• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Mild senile dementia of the Alzheimer type: 2. Longitudinal assessment.

作者信息

Berg L, Miller J P, Storandt M, Duchek J, Morris J C, Rubin E H, Burke W J, Coben L A

机构信息

Alzheimer's Disease Research Center, Department of Neurology and Neurological Surgery, Washington University School of Medicine, St Louis, MO 63110.

出版信息

Ann Neurol. 1988 May;23(5):477-84. doi: 10.1002/ana.410230509.

DOI:10.1002/ana.410230509
PMID:3389756
Abstract

Forty-three subjects with mild senile dementia of the Alzheimer type (SDAT, so-called probable Alzheimer's disease) were studied longitudinally by serial administration of several tests to rate dementia. Comparison was made with 58 healthy elderly controls. The clinical diagnosis was confirmed in all 16 autopsies. At 5 years after entry into the study, the cumulative rate of nursing home placement was 73%, and of death, 30%, rising at 7 years to 84% and 44%, respectively. Four of six clinical measures of dementia were found to correlate with the natural history of SDAT. Several measures are better than a single one in carrying out longitudinal studies of the disorder.

摘要

相似文献

1
Mild senile dementia of the Alzheimer type: 2. Longitudinal assessment.
Ann Neurol. 1988 May;23(5):477-84. doi: 10.1002/ana.410230509.
2
Mild senile dementia of the Alzheimer type: 3. Longitudinal and cross-sectional assessment.
Ann Neurol. 1990 Nov;28(5):648-52. doi: 10.1002/ana.410280508.
3
Weight loss and senile dementia in an institutionalized elderly population.
J Am Diet Assoc. 1989 Jun;89(6):790-2.
4
A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.一项在养老院环境中进行的关于多奈哌齐治疗阿尔茨海默病患者疗效和安全性的随机、双盲、安慰剂对照研究。
J Am Geriatr Soc. 2001 Dec;49(12):1590-9.
5
[The Zurich prospective dementia study 1987-1993].
Praxis (Bern 1994). 1997 Jun 11;86(24):1021-8.
6
The need for a consensus in the use of assessment tools for Alzheimer's disease: the Feasibility Study (assessment tools for dementia in Alzheimer Centres across Europe), a European Alzheimer's Disease Consortium's (EADC) survey.阿尔茨海默病评估工具使用达成共识的必要性:可行性研究(欧洲各地阿尔茨海默病中心的痴呆评估工具),欧洲阿尔茨海默病协会(EADC)的一项调查。
Int J Geriatr Psychiatry. 2005 Aug;20(8):744-8. doi: 10.1002/gps.1355.
7
[Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].[简短认知功能测试组合(B2C)的验证。在精神科实践中筛查阿尔茨海默病和抑郁症的价值]
Encephale. 2003 May-Jun;29(3 Pt 1):266-72.
8
Aphasia in senile dementia of the Alzheimer type.
Ann Neurol. 1988 Apr;23(4):365-70. doi: 10.1002/ana.410230409.
9
Validation of clinical diagnostic criteria for Alzheimer's disease.阿尔茨海默病临床诊断标准的验证
Ann Neurol. 1988 Jul;24(1):17-22. doi: 10.1002/ana.410240105.
10
Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention.轻度阿尔茨海默型老年痴呆症。4. 干预措施评估。
Ann Neurol. 1992 Mar;31(3):242-9. doi: 10.1002/ana.410310303.

引用本文的文献

1
Clinical progression on CDR-SB©: Progression-free time at each 0.5 unit level in dominantly inherited and sporadic Alzheimer's disease populations.基于CDR-SB©的临床进展:显性遗传和散发性阿尔茨海默病群体中每0.5单位水平的无进展时间。
Alzheimers Dement. 2025 Sep;21(9):e70643. doi: 10.1002/alz.70643.
2
Clinical Progression on CDR-SB: Progression Free Time at Each 0.5-unit Level in Dominantly Inherited and Sporadic Alzheimer's Disease Populations.CDR-SB的临床进展:显性遗传和散发性阿尔茨海默病群体中每0.5个单位水平的无进展时间
medRxiv. 2025 Feb 20:2025.02.17.25322322. doi: 10.1101/2025.02.17.25322322.
3
MRI-guided clustering of patients with mild dementia due to Alzheimer's disease using self-organizing maps.
使用自组织映射对阿尔茨海默病所致轻度痴呆患者进行磁共振成像引导的聚类分析
Neuroimage Rep. 2024 Dec;4(4). doi: 10.1016/j.ynirp.2024.100227. Epub 2024 Nov 18.
4
Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology.塞莫瑞单抗对阿尔茨海默病病理生理学血浆和脑脊液生物标志物的药效学作用。
Alzheimers Dement. 2024 Dec;20(12):8855-8866. doi: 10.1002/alz.14346. Epub 2024 Nov 8.
5
CSF complement proteins are elevated in prodromal to moderate Alzheimer's disease patients and are not altered by the anti-tau antibody semorinemab.脑脊液补体蛋白在阿尔茨海默病前驱期至中度患者中升高,而抗 tau 抗体 semorinemab 不会改变其水平。
Alzheimers Dement. 2024 Nov;20(11):7940-7953. doi: 10.1002/alz.14271. Epub 2024 Oct 6.
6
Comparing balance using the BESTest in Alzheimer, Huntington and Parkinson disease.比较阿尔茨海默病、亨廷顿病和帕金森病中使用 BESTest 的平衡情况。
Neurodegener Dis Manag. 2024;14(3-4):87-96. doi: 10.1080/17582024.2024.2388507. Epub 2024 Aug 19.
7
Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease.利用显性遗传性阿尔茨海默病临床试验数据,通过潜在类别分析检验淀粉样蛋白减少作为替代终点。
Alzheimers Dement. 2024 Apr;20(4):2698-2706. doi: 10.1002/alz.13735. Epub 2024 Feb 23.
8
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet.随机、Ⅱ期研究 Semorinemab 在轻度至中度阿尔茨海默病患者中的安全性和疗效:Lauriet.
Neurology. 2023 Oct 3;101(14):e1391-e1401. doi: 10.1212/WNL.0000000000207663. Epub 2023 Aug 29.
9
Cancer History Avoids the Increase of Senescence Markers in Peripheral Cells of Amnestic Mild Cognitive Impaired Patients.癌症病史可避免遗忘型轻度认知障碍患者外周细胞衰老标志物的增加。
Int J Mol Sci. 2023 Apr 17;24(8):7364. doi: 10.3390/ijms24087364.
10
Cognitive Aging with Dementia, Mild Cognitive Impairment, or No Impairment: A Comparison of Same- and Mixed-Sex Couples.认知老化伴痴呆、轻度认知障碍或无认知障碍:同性别和混合性别夫妇的比较。
J Alzheimers Dis. 2023;92(1):109-128. doi: 10.3233/JAD-220309.